<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373516</url>
  </required_header>
  <id_info>
    <org_study_id>QRX-101-CLIN-003</org_study_id>
    <nct_id>NCT00373516</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Study of the Safety and Efficacy of Two Dosing Regimens of QRX-101 (Becocalcidiol) Ointment in the Treatment of Plaque-Type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QuatRx Pharmaceuticals Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QuatRx Pharmaceuticals Company</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of
      QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when
      applied topically twice daily for 8 weeks
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date>March 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dichotomized Physician’s Static Global Assessment of Overall Lesion Severity (PGA)at Week 8</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change from Baseline in Psoriasis Symptom Severity (PSS)Scale at Week 8</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dichotomized PGA at weeks 2 and 4</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal PGA at weeks 2, 4, and 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline PSS at weeks 2 and 4</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal PSS at weeks 2, 4, and 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual symptom scores (erythema, induration, and scaling) at weeks 2, 4, and 8</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body surface area (BSA) involvement at weeks 2, 4, and 8</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle (Placebo) applied BID</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QRX-101 75 mcg/g ointment applied QD</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QRX-101 75 mcg/g ointment applied BID</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of stable plaque-type psoriasis affecting 2% to 10% of the
             subject’s body surface area

          -  Psoriasis of a severity that is appropriate for treatment with topical therapy; PGA of
             at least 3 (moderate) at baseline; PSS of at least 7, and with no individual symptom
             score (erythema, induration, or scaling) less than 2

          -  Subject must sign the IRB approved informed consent and agree to follow dosing
             instructions and complete required clinic visits.

        Exclusion Criteria:

          -  Pregnant or nursing females

          -  Systemic corticosteroids, methotrexate, cyclosporine, systemic retinoids, prolonged
             sun exposure or ultraviolet light therapy within 4 weeks of dosing

          -  Topical corticosteroids, retinoids, calcipotriene, coal tar, anthralin, or any other
             treatment indicated for psoriasis within 2 weeks of dosing

          -  Untreated bacterial, tubercular, fungal or any viral lesion of the skin

          -  Biologic agents/monoclonal antibodies in the last 6 months

          -  Currently using lithium or plaquenil

          -  Currently using a beta-blocking medication or thiazide diuretic and the dose has not
             been stabilized for at least 6 months

          -  History of hypercalcemia or evidence of vitamin D toxicity

          -  Current or history of melanoma skin cancer in the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Temple</city>
        <state>Pennsylvania</state>
        <zip>19560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol. 1999 Aug;141(2):274-8.</citation>
    <PMID>10468799</PMID>
  </reference>
  <reference>
    <citation>Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol. 1993 Jul;129(1):74-6.</citation>
    <PMID>8369213</PMID>
  </reference>
  <reference>
    <citation>Bourke JF, Berth-Jones J, Mumford R, Iqbal SJ, Hutchinson PE. High dose topical calcipotriol consistently reduces serum parathyroid hormone levels. Clin Endocrinol (Oxf). 1994 Sep;41(3):295-7.</citation>
    <PMID>7955435</PMID>
  </reference>
  <reference>
    <citation>Bourke JF, Iqbal SJ, Hutchinson PE. Vitamin D analogues in psoriasis: effects on systemic calcium homeostasis. Br J Dermatol. 1996 Sep;135(3):347-54. Review.</citation>
    <PMID>8949424</PMID>
  </reference>
  <reference>
    <citation>Frappaz A, Thivolet J. (1993). Calcipotriol in combination with PUVA: A randomized double-blind placebo study in severe psoriasis. European Journal of Dermatology. 3:351-354.</citation>
  </reference>
  <reference>
    <citation>Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002 Jun;46(6):850-60.</citation>
    <PMID>12063481</PMID>
  </reference>
  <reference>
    <citation>Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001 Mar;137(3):280-4.</citation>
    <PMID>11255325</PMID>
  </reference>
  <reference>
    <citation>Lamba S, Lebwohl M. Combination therapy with vitamin D analogues. Br J Dermatol. 2001 Apr;144 Suppl 58:27-32. Review.</citation>
    <PMID>11501510</PMID>
  </reference>
  <reference>
    <citation>Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001 Oct;45(4):487-98; quiz 499-502. Review.</citation>
    <PMID>11568737</PMID>
  </reference>
  <reference>
    <citation>Salmhofer W, Maier H, Soyer HP, Hönigsmann H, Hödl S. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Derm Venereol Suppl (Stockh). 2000;(211):5-8.</citation>
    <PMID>11234559</PMID>
  </reference>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2006</study_first_submitted>
  <study_first_submitted_qc>September 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <last_update_submitted>September 6, 2006</last_update_submitted>
  <last_update_submitted_qc>September 6, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2006</last_update_posted>
  <keyword>psoriasis</keyword>
  <keyword>topical therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

